Sjögren's disease & overlap diseases
Association of Combined Anti‐Ro52 / TRIM21 and Anti‐Ro60 / SSA Antibodies With Increased Sjögren Disease Severity Through Interferon Pathway Activation
Authors' conclusion
These results suggest that the combination of anti-Ro52/TRIM21 and anti-Ro60/SSA antibodies is associated with a clinical, biologic, and transcriptional profile linked to greater disease severity in SjD through the potentiation of the interferon pathway activation by anti-Ro52/TRIM21 antibodies.
Study context
- Population
- Patients with Sjögren disease (SjD) from the European PRECISESADS and Brittany DIApSS cohortsPRECISESADS 376 · European PRECISESADS 376 · Brittany DIApSS 146
- Exposure
- Ro52+/Ro60+ vs Ro52-/Ro60-, Ro52+ and Ro60+ patients with SjD
- Outcome
- Clinical and biologic features by anti-Ro52/Ro60 status (DIApSS cohort)
Methodological detailstwo cohorts (PRECISESADS, DIApSS), whole-blood RNA sequencing, type I and II interferon signatures
- Two cohorts (PRECISESADS, DIApSS)
- Whole-blood RNA sequencing
- Type I and II interferon signatures
Main finding
As reported in the abstract
- Parotidomegaly, Ro52+/Ro60+ vs other groups
- 33.3% vs 0%-11%
- Higher β2-microglobulin in Ro52+/Ro60+ vs other groups
- P = 0.0002
- Higher total immunoglobulin in Ro52+/Ro60+ vs other groups
- P < 0.0001
- Higher ESR in Ro52+/Ro60+ vs other groups
- P = 0.002
- Rheumatoid factor (RF) positivity, Ro52+/Ro60+ vs other groups
- 66.2% vs 20.8%-25%
Observational data: associations, not effects.
Further findings
Clinical and biologic features in Ro52+/Ro60+ (PRECISESADS cohort)
- Increased arthritis
- P = 0.046
- Increased inflammation
- P = 0.005
- Increased hypergammaglobulinemia
- P < 0.0001
- Increased positive RF
- P < 0.0001
- Increased leukopenia
- P = 0.004
- Increased lymphopenia
- P = 0.009
Cumulative ESSDAI
- Disparities confirmed
- P = 0.002
Transcriptome analysis
- Anti-Ro52/TRIM21 positivity linked to interferon pathway activation
Original publication
Association of Combined Anti‐Ro52 / TRIM21 and Anti‐Ro60 / SSA Antibodies With Increased Sjögren Disease Severity Through Interferon Pathway Activation. Arthritis Rheumatol. Published 14 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →